Eduardo Ferrero Herrero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eduardo Ferrero Herrero has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ana Isabel Pérez Zapata
Hospital Royo Villanova, Zaragoza, Spain
2 shared publications - Ana Peñas
Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
2 shared publications - Cesar Quintela
Department of Chemical and Biochemical Engineering, Technical University of Denmark, 2800 Kongens Lyngby, Denmark
2 shared publications - Cristina Sánchez-Ramos
Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
2 shared publications - Elias Rodriguez-Cuellar
Sección de Cirugía Esofagogástrica y Bariátrica, Hospital Universitario 12 de Octubre, Madrid, Spain
2 shared publications - Francisco-Javier García-Borda
Hospital Universitario 12 de Octubre, Av. Cordoba Km. 5.4, 28041 Madrid, Spain
2 shared publications
Latest Publications
- 7 August 2025
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Glycoprotein Determination with NMR Spectroscopy to Evaluate the Effect of Metabolic Surgery over the Proinflammatory State of Patients with Obesity
Aim Patients with obesity present with a proinflammatory state generally quantified by measuring acute-phase proteins (APP) such as C reactive protein (CPR) which shows however great variability. The determination of glycoproteins by using MRI spectroscopy, specifically acetyl groups of N-acetylglucosamine and N-acetylgalactosamine (GlycA), and acetyl groups of N-acetylneuraminic acid (GlycB), allows us to measure the aforementioned proinflammatory state with less interindividual variability than other biomarkers such as CPR, high-sensitivity CPR (hsCPR), or IL-6. The aim of this study is to show the influence of metabolic surgery over highly sensitive inflammatory markers (GlycA, Glyc B, and Glyc F). Material and Methods This prospective observational study included 52 patients undergoing metabolic surgery. Plasma levels of GlycA, GlycB, GlycF, and ratios HWGlycA and HWGlycB were measured before and 18 months after surgery. Results The cohort had a mean age of 46.3 years, 63.5% were women, with a mean BMI of 43.6 kg/m2, and abdominal circumference of 133.5 cm. Surgical techniques included BRYGB (55.7%), RYGB (19.2%), and SG (17.3%). GlycA decreased significantly postoperatively (mean difference: − 79.3 units; Cohen’s d = 1.99), as did GlycB (− 35.9; d = 1.88) and GlycF (− 43.7; d = 2.22), with all p < 0.001. Conclusions Metabolic surgery significantly reduces the proinflammatory state in patients with obesity, as demonstrated by large effect sizes and reductions in NMR-measured glycoproteins. These markers may offer a reliable method to monitor inflammation beyond traditional acute-phase reactants.
- 7 August 2025
- Published by Springer Nature in Obesity Surgery
- p. 1-8
Glycoprotein Determination with NMR Spectroscopy to Evaluate the Effect of Metabolic Surgery over the Proinflammatory State of Patients with Obesity
Aim Patients with obesity present with a proinflammatory state generally quantified by measuring acute-phase proteins (APP) such as C reactive protein (CPR) which shows however great variability. The determination of glycoproteins by using MRI spectroscopy, specifically acetyl groups of N-acetylglucosamine and N-acetylgalactosamine (GlycA), and acetyl groups of N-acetylneuraminic acid (GlycB), allows us to measure the aforementioned proinflammatory state with less interindividual variability than other biomarkers such as CPR, high-sensitivity CPR (hsCPR), or IL-6. The aim of this study is to show the influence of metabolic surgery over highly sensitive inflammatory markers (GlycA, Glyc B, and Glyc F). Material and Methods This prospective observational study included 52 patients undergoing metabolic surgery. Plasma levels of GlycA, GlycB, GlycF, and ratios HWGlycA and HWGlycB were measured before and 18 months after surgery. Results The cohort had a mean age of 46.3 years, 63.5% were women, with a mean BMI of 43.6 kg/m2, and abdominal circumference of 133.5 cm. Surgical techniques included BRYGB (55.7%), RYGB (19.2%), and SG (17.3%). GlycA decreased significantly postoperatively (mean difference: − 79.3 units; Cohen’s d = 1.99), as did GlycB (− 35.9; d = 1.88) and GlycF (− 43.7; d = 2.22), with all p < 0.001. Conclusions Metabolic surgery significantly reduces the proinflammatory state in patients with obesity, as demonstrated by large effect sizes and reductions in NMR-measured glycoproteins. These markers may offer a reliable method to monitor inflammation beyond traditional acute-phase reactants.
- 16 April 2024
- Published by Dykinson, S.L. in Archivos de Cirugía
- Vol. 2-2024 (2-2024)
Nota editorial. Tecnología de vanguardia en la cirugía oncológica colorrectal (Eduardo Ferrero Herrero)
Nota editorial. Tecnología de vanguardia en la cirugía oncológica colorrectal Cutting-edge technology in colorectal oncological surgery E. Ferrero Herrero* * Servicio de Cirugía General, Aparato Digestivo y Trasplante de Órganos Abdominales, Hospital Universitario 12 de Octubre, Madrid. eduardo.ferrero@salud.madrid.org DOI: https://doi.org/10.14679/3507 Palabras clave: Tecnología innovadora, cirugía oncológica colorrectal. Key words: Cutting-edge technology, colorectal … Continue reading Tecnología de vanguardia en la cirugía oncológica colorrectal
- 16 April 2024
- Published by Dykinson, S.L. in Archivos de Cirugía
- Vol. 2-2024 (2-2024)
Nota editorial. Tecnología de vanguardia en la cirugía oncológica colorrectal (Eduardo Ferrero Herrero)
Nota editorial. Tecnología de vanguardia en la cirugía oncológica colorrectal Cutting-edge technology in colorectal oncological surgery E. Ferrero Herrero* * Servicio de Cirugía General, Aparato Digestivo y Trasplante de Órganos Abdominales, Hospital Universitario 12 de Octubre, Madrid. eduardo.ferrero@salud.madrid.org DOI: https://doi.org/10.14679/3507 Palabras clave: Tecnología innovadora, cirugía oncológica colorrectal. Key words: Cutting-edge technology, colorectal … Continue reading Tecnología de vanguardia en la cirugía oncológica colorrectal
- Open Access
- 29 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6453
Evaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
Metabolic adaptations are a hallmark of cancer and may be exploited to develop novel diagnostic and therapeutic tools. Only about 50% of the patients who undergo thyroidectomy due to suspicion of thyroid cancer actually have the disease, highlighting the diagnostic limitations of current tools. We explored the possibility of using non-invasive blood tests to accurately diagnose thyroid cancer. We analyzed blood and thyroid tissue samples from two independent cohorts of patients undergoing thyroidectomy at the Hospital Universitario 12 de Octubre (Madrid, Spain). As expected, histological comparisons of thyroid cancer and hyperplasia revealed higher proliferation and apoptotic rates and enhanced vascular alterations in the former. Notably, they also revealed increased levels of membrane-bound phosphorylated AKT, suggestive of enhanced glycolysis, and alterations in mitochondrial sub-cellular distribution. Both characteristics are common metabolic adaptations in primary tumors. These data together with reduced mtDNA copy number and elevated levels of the mitochondrial antioxidant PRX3 in cancer tissue samples suggest the presence of mitochondrial oxidative stress. In plasma, cancer patients showed higher levels of cfDNA and mtDNA. Of note, mtDNA plasma levels inversely correlated with those in the tissue, suggesting that higher death rates were linked to lower mtDNA copy number. In PBMCs, cancer patients showed higher levels of PGC-1α, a positive regulator of mitochondrial function, but this increase was not associated with a corresponding induction of its target genes, suggesting a reduced activity in cancer patients. We also observed a significant difference in the PRDX3/PFKFB3 correlation at the gene expression level, between carcinoma and hyperplasia patients, also indicative of increased systemic metabolic stress in cancer patients. The correlation of mtDNA levels in tissue and PBMCs further stressed the interconnection between systemic and tumor metabolism. Evaluation of the mitochondrial gene ND1 in plasma, PBMCs and tissue samples, suggested that it could be a good biomarker for systemic oxidative metabolism, with ND1/mtDNA ratio positively correlating in PBMCs and tissue samples. In contrast, ND4 evaluation would be informative of tumor development, with ND4/mtDNA ratio specifically altered in the tumor context. Taken together, our data suggest that metabolic dysregulation in thyroid cancer can be monitored accurately in blood samples and might be exploited for the accurate discrimination of cancer from hyperplasia.
- 29 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6453
Open AccessEvaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
Metabolic adaptations are a hallmark of cancer and may be exploited to develop novel diagnostic and therapeutic tools. Only about 50% of the patients who undergo thyroidectomy due to suspicion of thyroid cancer actually have the disease, highlighting the diagnostic limitations of current tools. We explored the possibility of using non-invasive blood tests to accurately diagnose thyroid cancer. We analyzed blood and thyroid tissue samples from two independent cohorts of patients undergoing thyroidectomy at the Hospital Universitario 12 de Octubre (Madrid, Spain). As expected, histological comparisons of thyroid cancer and hyperplasia revealed higher proliferation and apoptotic rates and enhanced vascular alterations in the former. Notably, they also revealed increased levels of membrane-bound phosphorylated AKT, suggestive of enhanced glycolysis, and alterations in mitochondrial sub-cellular distribution. Both characteristics are common metabolic adaptations in primary tumors. These data together with reduced mtDNA copy number and elevated levels of the mitochondrial antioxidant PRX3 in cancer tissue samples suggest the presence of mitochondrial oxidative stress. In plasma, cancer patients showed higher levels of cfDNA and mtDNA. Of note, mtDNA plasma levels inversely correlated with those in the tissue, suggesting that higher death rates were linked to lower mtDNA copy number. In PBMCs, cancer patients showed higher levels of PGC-1α, a positive regulator of mitochondrial function, but this increase was not associated with a corresponding induction of its target genes, suggesting a reduced activity in cancer patients. We also observed a significant difference in the PRDX3/PFKFB3 correlation at the gene expression level, between carcinoma and hyperplasia patients, also indicative of increased systemic metabolic stress in cancer patients. The correlation of mtDNA levels in tissue and PBMCs further stressed the interconnection between systemic and tumor metabolism. Evaluation of the mitochondrial gene ND1 in plasma, PBMCs and tissue samples, suggested that it could be a good biomarker for systemic oxidative metabolism, with ND1/mtDNA ratio positively correlating in PBMCs and tissue samples. In contrast, ND4 evaluation would be informative of tumor development, with ND4/mtDNA ratio specifically altered in the tumor context. Taken together, our data suggest that metabolic dysregulation in thyroid cancer can be monitored accurately in blood samples and might be exploited for the accurate discrimination of cancer from hyperplasia.
- Open Access
- 10 February 2023
- Published by MDPI AG in Preprints.org
Evaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
Metabolic adaptations are a hallmark of cancer and may be exploited to develop novel diagnostic and therapeutic tools. Only about 50% of the patients who undergo thyroidectomy due to suspicion of thyroid cancer actually have the disease, highlighting the diagnostic limitations of current tools. We explored the possibility of using non-invasive blood tests to accurately diagnose thyroid cancer. We analyzed blood and thyroid tissue samples from 2 independent cohorts of patients undergoing thyroidectomy at the Hospital Universitario 12 de Octubre (Madrid, Spain). As expected, histological comparisons of thyroid cancer and hyperplasia revealed higher proliferation and apoptotic rates and enhanced vascular alterations in the former. Notably, they also revealed increased levels of membrane-bound phosphorylated AKT, suggestive of enhanced glycolysis, and alterations in mitochondrial sub-cellular distribution. Both characteristics are common metabolic adaptations in primary tumors. These data together with reduced mtDNA copy number and elevated levels of the mitochondrial antioxidant Prx3 in cancer tissue samples suggest the presence of mitochondrial oxidative stress. In plasma, cancer patients showed higher levels of cfDNA and mtDNA. Of note, mtDNA plasma levels inversely correlated with those in the tissue, suggesting that higher death rates were linked to lower mtDNA copy number. In PBMCs, cancer patients showed higher levels of PGC-1, a positive regulator of mitochondrial function, but this increase was not associated with a corresponding induction of its target genes, suggesting a reduced activity in cancer patients. We also observed a significant difference in the PRDX3/PFKFB3 correlation at the gene expression level, between carcinoma and hyperplasia patients, also indicative of increased systemic metabolic stress in cancer patients. The correlation of mtDNA levels in tissue and PBMCs further stressed the interconnection between systemic and tumor metabolism. Evaluation of the mitochondrial gene ND1 in plasma, PBMCs and tissue samples, suggested that it could be a good biomarker for systemic oxidative metabolism, with ND1/mtDNA ratio positively correlating in PBMCs and tissue samples. In contrast, ND4 evaluation would be informative of tumor development, with ND4/mtDNA ratio specifically altered in the tumor context. Taken together, our data suggest that metabolic dysregulation in thyroid cancer can be monitored accurately in blood samples and might be exploited for the accurate discrimination of cancer from hyperplasia.
- 10 February 2023
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Mitochondrial Function in Blood Samples Shows Distinct Patterns in Subjects with Thyroid Carcinoma from Those with Hyperplasia
Metabolic adaptations are a hallmark of cancer and may be exploited to develop novel diagnostic and therapeutic tools. Only about 50% of the patients who undergo thyroidectomy due to suspicion of thyroid cancer actually have the disease, highlighting the diagnostic limitations of current tools. We explored the possibility of using non-invasive blood tests to accurately diagnose thyroid cancer. We analyzed blood and thyroid tissue samples from 2 independent cohorts of patients undergoing thyroidectomy at the Hospital Universitario 12 de Octubre (Madrid, Spain). As expected, histological comparisons of thyroid cancer and hyperplasia revealed higher proliferation and apoptotic rates and enhanced vascular alterations in the former. Notably, they also revealed increased levels of membrane-bound phosphorylated AKT, suggestive of enhanced glycolysis, and alterations in mitochondrial sub-cellular distribution. Both characteristics are common metabolic adaptations in primary tumors. These data together with reduced mtDNA copy number and elevated levels of the mitochondrial antioxidant Prx3 in cancer tissue samples suggest the presence of mitochondrial oxidative stress. In plasma, cancer patients showed higher levels of cfDNA and mtDNA. Of note, mtDNA plasma levels inversely correlated with those in the tissue, suggesting that higher death rates were linked to lower mtDNA copy number. In PBMCs, cancer patients showed higher levels of PGC-1, a positive regulator of mitochondrial function, but this increase was not associated with a corresponding induction of its target genes, suggesting a reduced activity in cancer patients. We also observed a significant difference in the PRDX3/PFKFB3 correlation at the gene expression level, between carcinoma and hyperplasia patients, also indicative of increased systemic metabolic stress in cancer patients. The correlation of mtDNA levels in tissue and PBMCs further stressed the interconnection between systemic and tumor metabolism. Evaluation of the mitochondrial gene ND1 in plasma, PBMCs and tissue samples, suggested that it could be a good biomarker for systemic oxidative metabolism, with ND1/mtDNA ratio positively correlating in PBMCs and tissue samples. In contrast, ND4 evaluation would be informative of tumor development, with ND4/mtDNA ratio specifically altered in the tumor context. Taken together, our data suggest that metabolic dysregulation in thyroid cancer can be monitored accurately in blood samples and might be exploited for the accurate discrimination of cancer from hyperplasia.
- 31 December 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (3) , 965-968
Ligamentum Teres Cardiopexy Might Not Prevent Gastro-esophageal Reflux After Laparoscopic Sleeve Gastrectomy: Case Series
Roux-en-Y gastric bypass (RYGB) is considered the gold standard procedure in patients with obesity and gastroesophageal reflux (GERD), but in patients with preoperative hiatal hernia (HH) or GERD, who are unfit for RYGB, there are no clear guidelines. Ligamentum teres cardiopexy (LTC) has been proposed as an effective alternative. The purpose of this study was to analyze medium-term results of LTC procedure associated with laparoscopic sleeve gastrectomy (LSG) in patients with GERD or HH, according to the absence of pathologic acid reflux in esophageal 24 h pH monitoring test, symptom release, or PPI reduction. Five patients underwent LSG-LTC between March 2018 and October 2019. In one patient, the effectiveness of LTC as an anti-reflux procedure could not be assessed because of conversion to RYGB was required. After a follow-up period of 30 [24–42] months and excessive BMI loss of 62.74 ± 18.18%, GERD recurrence was observed in 75% of patients. The study was discontinued due to unsatisfactory preliminary results with LTC. Our results suggest that LTC might not prevent GERD after LSG in patients with preoperative GERD or HH. Graphical Abstract
- 31 December 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 33 (3) , 965-968
Ligamentum Teres Cardiopexy Might Not Prevent Gastro-esophageal Reflux After Laparoscopic Sleeve Gastrectomy: Case Series
Roux-en-Y gastric bypass (RYGB) is considered the gold standard procedure in patients with obesity and gastroesophageal reflux (GERD), but in patients with preoperative hiatal hernia (HH) or GERD, who are unfit for RYGB, there are no clear guidelines. Ligamentum teres cardiopexy (LTC) has been proposed as an effective alternative. The purpose of this study was to analyze medium-term results of LTC procedure associated with laparoscopic sleeve gastrectomy (LSG) in patients with GERD or HH, according to the absence of pathologic acid reflux in esophageal 24 h pH monitoring test, symptom release, or PPI reduction. Five patients underwent LSG-LTC between March 2018 and October 2019. In one patient, the effectiveness of LTC as an anti-reflux procedure could not be assessed because of conversion to RYGB was required. After a follow-up period of 30 [24–42] months and excessive BMI loss of 62.74 ± 18.18%, GERD recurrence was observed in 75% of patients. The study was discontinued due to unsatisfactory preliminary results with LTC. Our results suggest that LTC might not prevent GERD after LSG in patients with preoperative GERD or HH. Graphical Abstract